Skip to content

Epicardial Adipose Tissue Volume and Attenuation in Acute Ischemic Stroke

Effect of Epicardial Adipose Tissue Volume and Attenuation on Clinical Outcomes After Acute Ischemic Stroke

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05631808
Acronym
EATVAS
Enrollment
200
Registered
2022-11-30
Start date
2023-02-06
Completion date
2025-03-01
Last updated
2023-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

Ischemic stroke, Epicardial adipose tissue, Obesity

Brief summary

Excessive accumulation or abnormal distribution of adipose tissue is a recognized risk factor for ischemic stroke. However, the impact of overweight or obesity on clinical outcomes of ischemic stroke is uncertain. The proposition of obesity paradox in stroke patients makes secondary prevention ambiguous for patients with ischemic stroke and overweight or obesity. Body mass index (BMI) or abdominal visceral fat area was used to measure obesity in previous studies. Epicardial adipose tissue (EAT) is a unique visceral fat, which has higher expression of proinflammatory genes than subcutaneous fat and abdominal visceral fat. And inflammation is closely related to the prognosis of ischemic stroke. In this study, the investigators assume EAT volume or attenuation evaluated by chest computed tomography (CT) scan might affect the prognosis of patients with acute ischemic stroke (AIS). Patients with the first acute ischemic stroke will be stratified into tertile groups based on EAT volume or attenuation. The primary endpoint measure is the proportion of patients with a favorable recovery of nerve function deficiency assessed by Modified Rankin Scale (mRS≤2) at 90 days after the onset of symptoms. Secondary endpoints include the following: the percentage of functional recovery measured by the Barthel Index (BI) at day 90 after stroke onset, the propotion of clinical improvement (with an improvement of ≥ 4 points on the National Institute of Health Stroke Scale score or the resolution of the neurologic deficit) or neurological deterioration (with a decline by ≥ 4 points in the total National Institute of Health Stroke Scale score) at day 7 after stroke onset, incidence of hemorrhagic transformation and mortality within 7 days of symptom onset.

Interventions

OTHEREpicardial adipose tissue volume and attenuation

Epicardial adipose tissue volume and attenuation assessed by CT are the exposure factors in this study.

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient is between 18 and 80 years of old; * Acute ischemic stroke(AIS)is diagnosed by brain imaging, and this is the first ischemic stroke event; * Patient is admitted to hospital within 72 hours after stroke onset; * Modified Rankin scale score (mRS) ≤2 before onset; * Patient undergoes chest CT scanning during hospitalization; * Provision of written informed consent.

Exclusion criteria

* Pregnant or nursing women; * Complicated with cerebral hemorrhage showed by cranial CT on admission; * Patient had brain tumor, intracranial aneurysm, arteriovenous malformation, or cerebral hemorrhage or underwent brain surgery in the past; * Severe cardiac, liver, pulmonary, or kidney disease, malignancy, severe coagulation dysfunction, and systemic organ dysfunction; * Failure to accomplish 7-day and 3-month follow up.

Design outcomes

Primary

MeasureTime frameDescription
Modified Rankin scale (mRS)90 days after stroke onset.Assess patients' prognosis by the score of modified Rankin Scale. In the mRS, the lowest score is 0, the highest score is 6, and higher scores mean worse outcome. A score of 0 indicates the patients have no symptoms at all, and a score of 6 indicates the patients are dead. In this study, we evaluate patient's outcomes by the following criteria. A favorable outcome is defined as an mRS score of 0 to 2, an excellent outcome is defined as an mRS score of 0 to 1, whereas a poor outcome is defined as mRS\>2.

Secondary

MeasureTime frameDescription
Barthel Index (BI)90 days after stroke onset.The percentage of functional recovery from baseline to 90 days after stroke onset, is measured by the Barthel Index (BI). BI score from 0-100, higher scores mean better outcome. We measure how many patients achieve 95 for the BI.
The change of NIHSS score7 days after stroke onset.The percentage of functional recovery or deterioration from baseline to 7 days after stroke onset, is measured by the National Institute of Health Stroke Scale, short for NIHSS. NIHSS score from 0-42, higher scores mean worse outcome. We define early functional improvement as an improvement of ≥ 4 points on the NIHSS or the resolution of the neurologic deficit, and early neurological deterioration as a decline by ≥ 4 points in the total NIHSS score within 7 days of symptom onset.
Hemorrhagic transformationwithin 7 days of symptom onsetHemorrhagic transformation is considered present when follow-up MRI or CT scans reveal findings consistent with a newly developed extravasation of blood. Symptomatic intracranial hemorrhage is defined as extravascular blood in the brain confirmed by neuroimaging and is associated with neurological deterioration of ≥ 4 points on the NIHSS.
Mortalitywithin 7 days of symptom onsetWe evaluate early mortality due to any cause within 7 days of symptom onset.

Countries

China

Contacts

Primary ContactGuogang Luo, MD, PhD
lguogang@163.com0086-13991974085
Backup ContactMengmeng Li
2921887723@qq.com0086-17899109500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026